Commercial Excellence 
In the past five years, the Department of Justice (DOJ) has levied almost $22 billion in fines against pharmaceutical companies for compliance violations. In addition to these fines, there are significant costs associated with negative publicity and damaged company reputations.
Compliance standards are becoming increasingly rigid with Corporate Integrity Agreements (CIAs) and Risk Evaluation and Mitigation Strategies (REMS) requirements being imposed on pharmaceutical firms that have violated laws or ethical standards. Recent CIAs have included requirements for executive board oversight and manager certifications, as well as field force monitoring and reporting requirements. These requirements can create strife between sales representatives and compliance officers. They can also lead to decreased sales, uncertainty within the organization, and external scrutiny.
When designing a field based monitoring program, there are a variety of concerns that should be addressed. Among them are a lack of organizational commitment and a general disconnect between the intent of the compliance program and the actions of the field force.
Dr. Wendy Heckelman will explain the most common risks associated with the implementation of a compliance program and suggested best practices to address them.
What Will You Learn?
- Crucial Elements of an Effective Field Based Monitoring Program
- How to Design Compliance Training to Promote Behavioral Change
- What Good Compliant Sales Messaging Looks Like
Who Should Attend?
- Senior Compliance Officers
- Senior Sales Leaders
- Compliance Training Professionals
Can’t attend live? Register anyway – we will send you a link of the recording!
If you have any questions, contact us and we will get back to you as soon as possible.
